Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence.
about
Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaCosts and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical AntipsychoticsPaliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia.Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment.Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.
P2860
Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidence.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Comparative effectiveness of i ...... early postmarketing evidence.
@en
Comparative effectiveness of i ...... early postmarketing evidence.
@nl
type
label
Comparative effectiveness of i ...... early postmarketing evidence.
@en
Comparative effectiveness of i ...... early postmarketing evidence.
@nl
prefLabel
Comparative effectiveness of i ...... early postmarketing evidence.
@en
Comparative effectiveness of i ...... early postmarketing evidence.
@nl
P2093
P2860
P356
P1476
Comparative effectiveness of i ...... early postmarketing evidence.
@en
P2093
Deborah S K Thomas
Dilesh Doshi
Elaine H Morrato
Elizabeth J Campagna
Erik Muser
P2860
P356
10.2217/CER.14.50
P577
2014-09-24T00:00:00Z